drugset / Trial / NCT05872256

A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis

NCT05872256

NaSingle-groupOpen-labelTreatment

Summary

The objectives of this research are to demonstrate the following:1. To demonstrate improvement in hair growth and hair appearance following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.2. To demonstrate improvement in scalp itch reduction following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.3. To pictorially demonstrate improvement in moderate to severe scalp psoriasis with 12 weeks of once daily treatment with tazarotene/halobetasol lotion.4. To assessment patient perceptions of the value of a lotion in the treatment of moderate to severe scalp psoriasis.

Timeline

Start
2023-06-01
Primary completion
2023-11-13
Completion
2023-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Halobetasol Unknown 0.01 % Topical
Subject Tazarotene Small molecule 0.045 % Topical

Indications